Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535852 | 0.74 | HDAC6 (0.54) | HDAC6P2RX7MEN1KMT2AHDAC3 | |
| SCHEMBL10067533 | 0.73 | P2RX7 (0.67) | HDAC6P2RX7MEN1KMT2AHDAC3 | |
| SCHEMBL18088397 | 0.71 | HDAC6 (0.61) | HDAC6P2RX7MEN1KMT2AHDAC3 | |
| SCHEMBL18085885 | 0.71 | HDAC6 (0.57) | HDAC6P2RX7MEN1KMT2AHDAC3 | |
| SCHEMBL7367240 | 0.70 | ALDH1A1 (0.35) | — | |
| SCHEMBL9080180 | 0.66 | HDAC6 (0.54) | HDAC6P2RX7MEN1KMT2AHDAC3 | |
| SCHEMBL4930125 | 0.66 | — | — | |
| SCHEMBL20535185 | 0.65 | HDAC6 (1.00) | HDAC6P2RX7HDAC3HDAC1HDAC2 | |
| SCHEMBL1160892 | 0.65 | P2RX7 (0.55) | HDAC6P2RX7MEN1KMT2AHDAC3 | |
| SCHEMBL18460736 | 0.64 | HDAC6 (0.62) | HDAC6P2RX7MEN1KMT2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | claimed |
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | claimed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | HDAC6 1041/4885P2RX7 1784/4885MEN1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.